Physician profile
Phillip K Henderson
NPI 1144450792
$461,536.63
in general payments reported to CMS, 2019-2025
22 companies · $128K in 2025
The $128K reported for 2025 was more than what 99% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $119K · 2020: $25K · 2021: $64K · 2022: $34K · 2023: $33K · 2024: $59K · 2025: $128K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $154K · Travel and Lodging: $42K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $17K · Food and Beverage: $7,120 · Education: $46.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $153,745.06 |
| Travel and Lodging | $41,628.87 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $16,740.00 |
| Food and Beverage | $7,119.97 |
| Education | $46.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $144,729.41 | 2019-2025 | Epclusa, Livdelzi |
| Madrigal Pharmaceuticals | $132,285.15 | 2024-2025 | Rezdiffra, Resmetirom |
| Abbvie INC. | $110,662.61 | 2019-2025 | |
| Intercept Pharmaceuticals, INC. | $53,293.60 | 2019-2025 | Ocaliva |
| Novo Nordisk INC | $19,309.52 | 2025 | Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $246.80 | 2022-2025 | Entyvio, Gattex, Livtencity |
| Covidien Lp | $184.95 | 2020 | |
| Janssen Biotech, INC. | $138.92 | 2019-2024 | Stelara |
| Pfizer INC. | $100.28 | 2024 | |
| Celgene Corporation | $98.41 | 2023-2024 | Zeposia |
| Erbe USA INC | $90.00 | 2024-2025 | Vio3 |
| Ferring Pharmaceuticals INC. | $87.51 | 2022-2023 | Cimzia, Rebyota |
| Mallinckrodt Hospital Products INC. | $60.86 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $60.06 | 2022-2024 | Xifaxan |
| Fujifilm Wako Diagnostics U.S.A. Corporation | $50.00 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $41.57 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $18.59 | 2024 | Iqirvo |
| Echosens North America, INC. | $17.34 | 2019 | |
| Vbi Vaccine (Delaware) INC. | $17.15 | 2022 | |
| Ardelyx, INC. | $15.38 | 2023 | Ibsrela |
| Celltrion USA INC. | $14.93 | 2024 | Vegzelma |
| Organon LLC | $13.59 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phillip Henderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.